Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HRS-7058 in previously treated advanced or metastatic pancreatic adenocarcinoma with a mutation
CTR20261820Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-7058 in pancreatic cancer (PC), pancreatic adenocarcinoma (PDAC), sponsored by Shandong Sende. Started Jun 2026; status: active.
02
Drugs
HRS-7058
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20261820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261820.